Vol.56 No.3 May 2008

An open clinical study of arbekacin 200 mg q.d. in patients infected with methicillin-resistant Staphylococcus aureus (MRSA) -A clinical pharmacology study-

Naoki Aikawa, Shigeru Kohno, Mitsuo Kaku, Akira Watanabe, Keizo Yamaguchi and Yusuke Tanigawara

Jpn. J. Chemother. 56 (3): 299-312, 2008

Studies of Pseudomonas aeruginosa isolated in Public Fujioka General Hospital

Masayuki Tamura

Jpn. J. Chemother. 56 (3): 313-316, 2008

Postmarketing study of prulifloxacin tablets

Hitoshi Kawano, Saori Kawamata and Yoshikazu Sato

Jpn. J. Chemother. 56 (3): 317-329, 2008

Clinical effects of micafungin, a novel echinocandin antifungal agent, on systemic fungal infections in surgery, emergency, and intensive-care medicine; Evaluation using the AKOTT algorithm

Naoki Aikawa, Shinya Kusachi, Shigeto Oda, Yoshio Takesue and Hideharu Tanaka

Jpn. J. Chemother. 56 (3): 330-343, 2008

Antifungal activity of micafungin against clinical isolates of Candida and Aspergillus species -Second biennial surveillance report-

Intetsu Kobayashi, Makoto Suzuki, Takeshi Saika, Fumiaki Ikeda, Yasuhiro Hori, Satoru Matsumoto, Ikuo Kawamura, Takashi Yoshiyasu and Hisanori Horita

Jpn. J. Chemother. 56 (3): 344-352, 2008